Prevounce Health has launched Pylo GL1-LTE, a cellular-connected remote blood glucose meter for remote monitoring of patients.

This new clinically validated device is designed to enhance remote patient monitoring (RPM) programmes for diabetes management by ensuring reliable data transmission across the US.

It is equipped to allow seamless connection to multiple cellular networks.

The device is compatible with the Prevounce remote care management platform and can be integrated with other health software systems through the Pylo cloud API.

Prevounce's portfolio of Pylo cellular-connected devices also includes weight scales and blood pressure monitors.

Designed specifically for diabetic patients enrolled in RPM programmes, the Pylo GL1-LTE offers roaming 4G connectivity, requiring no patient configuration. It can securely send real-time glucose readings to care teams of patients.

The device has undergone rigorous testing, achieving US Food and Drug Administration (FDA) clearance and FCC certification.

It provides plasma glucose results with laboratory-grade accuracy.

Features such as an intuitive user interface, a simple test strip ejector, and a standard carrying case enhance the patient experience.

Prevounce founder and CEO Daniel Tashnek said: "Clinical evidence shows that remote blood glucose monitoring is associated with improved glycemic control for diabetic patients.

“Reliable devices and consistent readings are essential for RPM programs to realize their full clinical and financial potential. We're excited to introduce a new Pylo glucometer that is not only dependable and accurate but also comfortable and simple for patients to use."

Healthcare organisations can customise the GL1-LTE blood glucose meter to align with their brand identity.

Prevounce allows for the addition of logos, taglines, and patient inserts on the devices and their packaging, offering a consistent brand experience.